An investigator-initiated, multicenter, open-label, parallel arm, active comparator, randomized study to compare the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with left ventricular thrombus after acute myocardial infarction.

Acute mycocardial infarction (AMI), Left ventricular thrombosis.

Thrombus resolution will be evaluated by TTE (Transthoracic echocardiogram), preferably contrast-enhanced, at 3 months. Should TTE be inconclusive, cardiac magnet resonance imaging (MRI) or cardiac computed tomography (CCT) is recommended to evaluate the primary endpoint.

Clinically relevant bleeding - BARC (Bleeding Academy Research Consortium) 2, 3 or 5 bleeding., Major bleeding BARC 3 or 5 bleeding., Individual bleeding endpoints (Fatal bleeding, intracranial hemorrhage, GI bleeding, urogenital bleeding and bleeding of other sources)., Major adverse cardiovascular events (MACE). Composite of non-fatal myocardial infarction, non-fatal ischemic stroke and cardiovascular death., Net clinical benefit: Composite of MACE and BARC 2, 3 or 5 bleeding., Ischemic stroke and systemic embolism., Recurrence of LV thrombus at 12 months.

No related papers found yet.

Sweden